Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
CNS & Neurological Disorders - Drug Targets
Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Volume: 13 Issue: 6
Author(s): Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Export Options
About this article
Cite this article as:
Schier R. de Mello Alexandre, Ribeiro P. de Oliveira Natalia, Coutinho S. Danielle, Machado Sergio, Arias-Carrion Oscar, Crippa A. Jose, Zuardi W. Antonio, Nardi E. Antonio and Silva C. Adriana, Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114838
DOI https://dx.doi.org/10.2174/1871527313666140612114838 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Covid-19 on Mental Health: An Overview
Reviews on Recent Clinical Trials Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor
Mini-Reviews in Medicinal Chemistry Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Editorial (Thematic Special Issue: Coming of Age Online: Challenges of Treating the Internet Generation)
Adolescent Psychiatry Using Functional Neuroimaging to Investigate the Mechanisms of Action of Selective Serotonin Reuptake Inhibitors (SSRIs)
Current Pharmaceutical Design Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Predictive QSAR Modeling Workflow, Model Applicability Domains, and Virtual Screening
Current Pharmaceutical Design Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways
Current Neuropharmacology Design, Synthesis and Pharmacological Evaluation of HIV-1 Reverse Transcriptase Inhibition of New Indolin-2-Ones
Medicinal Chemistry Renin-Angiotensin-Aldosterone System and Migraine: A Systematic Review of Human Studies
Protein & Peptide Letters Cerebrospinal Fluid Proteins in the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders Time-resolved and in-situ X-ray scattering methods beyond photoactivation: Utilizing high-flux X-ray sources for the study of ubiquitous non-photoactive proteins
Protein & Peptide Letters Incorporation of Natural Renewable Components and Waste Byproducts to Benzoxazine Based High Performance Materials
Current Organic Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Neurotoxic Mechanism and Shortcomings of MPTP, 6-OHDA, Rotenone and Paraquat-induced Parkinson’s Disease Animal Models
Venoms and Toxins Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy NMDA-antagonism (Memantine): An Alternative Pharmacological Therapeutic Principle in Alzheimers and Vascular Dementia
Current Pharmaceutical Design